This is very interesting! This pending patent is 2 fold:
“detecting the presence of CCR5 on circulating tumor cells in a subject's sample; and
administering to the subject with CCR5 on the circulating tumors cells a CCR5 inhibitor to treat the cancer.”
I can definitely see why the TNBC injection didn’t occur as soon as we had hoped. I wonder if the TNBC interim results will or are in any way related to the approval of this patent?
Also, do you know if CYDY owns this patent with the acquisition of ProstaGene or if RP maintained this separately?
It specifically mentioned prostate cancer (RPs SME) and breast cancer (Cristofanilli SME) several times during the patent. I’m not sure if that a result of the indications they tested or not?.....I’m not very familiar with patent protocol.
“detecting the presence of CCR5 on circulating tumor cells in a subject's sample; and
administering to the subject with CCR5 on the circulating tumors cells a CCR5 inhibitor to treat the cancer.”
I can definitely see why the TNBC injection didn’t occur as soon as we had hoped. I wonder if the TNBC interim results will or are in any way related to the approval of this patent?
Also, do you know if CYDY owns this patent with the acquisition of ProstaGene or if RP maintained this separately?
It specifically mentioned prostate cancer (RPs SME) and breast cancer (Cristofanilli SME) several times during the patent. I’m not sure if that a result of the indications they tested or not?.....I’m not very familiar with patent protocol.
